Morgan Stanley Analyst Believe bluebird bio Ash Conf. Data Have Turned Favorable Risk/Reward Thesis Upside Down Due To Inability Of BB305 To Consitently Produce Enough Hb In Sickle Cell Patients, Removing Floor In Their Valuation